Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol

We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induc...

Full description

Saved in:
Bibliographic Details
Published inAdvances in Hematology Vol. 2010; no. 2010; pp. 217 - 219
Main Authors Pagnano, Kátia B. Barbosa, Duarte, Gustavo de Carvalho, Lorand-Metze, Irene, Delamain, Márcia Torresan, Miranda, Eliana Cristina, De Souza, Cármino Antonio
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Limiteds 2010
Hindawi Puplishing Corporation
Hindawi Publishing Corporation
Hindawi Limited
Subjects
Clinical Study
Online AccessGet full text

Cover

More Information
Summary:We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
Academic Editor: Jesus Fernando San Miguel
ISSN:1687-9104
1687-9112
DOI:10.1155/2010/672137